Depiction of an ovarian cancer blood test.
Chicago—Maintenance therapy with olaparib can improve outcomes in patients with platinum-sensitive, relapsed serous ovarian cancer, according to an updated analysis of the Phase II Study 19. Although olaparib maintenance therapy resulted in statistically significant improvements in progression-free survival (PFS) and time to first (TFST) and second subsequent therapy (TSST) or death, there was only an insignificant trend for improved